Morning Movers: Spectrum Pharmaceuticals (NASDAQ:SSPI) and Heckmann Corporation (NYSE:HEK)

New York, NY -- (SBWIRE) -- 03/13/2013 -- StockRunway.com issues special report on Morning Movers – Spectrum Pharmaceuticals (NASDAQ:SSPI) and Heckmann Corporation (NYSE:HEK).

Spectrum Pharmaceuticals (NASDAQ:SSPI) estimated that it would bring in no more than $90 million selling its Fusilev cancer medicine this year. That's a great decline from 2012's $204 million, and the stock is getting punished. SPPI declines 35 percent ahead of the bell on tradeMONSTER platform.

The forecast for the year would show a decline of almost 56 percent from Fusilev's 2012 total of $204.3 million, and it is much lower than experts’ estimation.

How shares of Spectrum Pharmaceuticals reacted on Wednesday? Find in this report

Spectrum Pharmaceuticals Inc. (SPPI) declined in premarket session on Wednesday following the pharmaceutical firm reported that sales of its drug Fusilev could drop critically this year.

The Henderson, Nev., firm’s stock began declining on Tuesday following it reported that it predicts Fusilev revenue to total in a range of $10 million and $15 million in the initial quarter and almost $80 million to $90 million for the year.

How Heckmann Corporation gained investors attention on Wednesday? Find out here

Heckmann Corporation (NYSE:HEK) shares rallied almost 12% on Tuesday after the drilling services firm posted a shocking profit for the Q4 and enhanced than predicted revenue.

Heckmann announced a profit of $5M, or 3 cents per share, while experts surveyed by FactSet predicted a loss of 3 cents per share. Revenue increased more than twofold to $113.2M, exceeding the average Wall Street target of $110.1M.

Shares of Heckmann Corporation (NYSE:HEK) were trading above the trend line with positive change of above 3% on last check.

About StockRunway.com
StockRunway.com is an Elite Financial Stock website catering to individual investors, fund managers, investment bankers and equity analysts. Whether you're new to penny stocks or a seasoned veteran, you'll find all the information you will need right here! Our research is a remarkable educational tool for everyone to utilize.

Sign up TODAY and join the vast amount of investors already benefiting from the best free alerts from StockRunway's service today!

Disclaimer
This report/release/advertisement is a commercial advertisement and is for general information purposes only. Never invest in any stock featured on our site, Press Releases or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: StockRunway.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. Read our Full Disclaimer by visiting our website.

Read Our Full Disclaimer at: http://www.stockrunway.com/disclaimer/